NephroGenex Inc

NephroGenex — Investor Presentation (November 2015)

40 slides from NephroGenex's investor presentation, Nov 12, 2015

  1. Slide 1: Corporate Presentation November 2015

    Corporate Presentation November 2015

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expec

  3. Slide 3: NephroGenex Investment Thesis

    NephroGenex Investment Thesis 3 Diabetic nephropathy is a major unmet need with a significant healthcare financial burden Pharmaceutical company developing therapies that target the underlying cause of kidney disease  Oral Pyridorin – for the prevention or slowing the progression of diabetic nephro

  4. Slide 4: NephroGenex Team

    NephroGenex Team Member Previous Affiliations/Positions Pierre Legault, Chief Executive Officer and President Sanofi-Aventis, President Worldwide Dermatology Eckerd, President Rite Aid, CAO OSI Pharmaceuticals, CFO Prosidion Ltd, CEO Board Member, NPS, Iroko, Tobira, Cyclacel, Forest Labs, others Dr

  5. Slide 5: NephroGenex Pipeline

    NephroGenex Pipeline Clinical Program Clinical Program / Indication Preclinical Phase 1 Phase 2 Phase 3 Worldwide Commercial Rights ORAL PYRIDORIN ® Diabetic Nephropathy I.V. PYRIDORIN ® Acute Kidney Injury Chronic oral dosing that targets the underlying metabolic pathophysiology of diabetic nephrop

  6. Slide 6: Oral Pyridorin – Significant Market Potential

    Oral Pyridorin – Significant Market Potential 6 Diabetic nephropathy progresses from microalbuminuria to macroalbuminuria, then to end stage renal disease (ESRD) and dialysis Estimated 31 million diabetics in the U.S. – 22 million diagnosed, 40% of whom exhibit kidney disease (France, Germany, and U

  7. Slide 7: Pathophysiology of Diabetic Complications

    7 Pathophysiology of Diabetic Complications

  8. Slide 8: Pyridorin – Mechanism of Action

    8 Pyridorin – Mechanism of Action

  9. Slide 9: Preclinical Overview: Pyridoxamine in Models of DN

    9 Other models:  Db/db diabetic mouse model of type 2 diabetic nephropathy 1  KK-A(y)/Ta diabetic mouse model of type 2 diabetic nephropathy 2  Obese Zucker fa/fa rat model of metabolic syndrome early nephropathy 3 Preclinical Overview: Pyridoxamine in Models of DN Control rats +/– pyridoxamine U

  10. Slide 10: Clinical Overview: Ph2 Data in Target Ph3 Population

    10 Clinical Overview: Ph2 Data in Target Ph3 Population (Type 2 Diabetes; SCr 1.3-3 mg/dL; Urinary Protein >1200 mg/g Cr; Stable SOC)

  11. Slide 11: Preclinical and Clinical Safety Profile

    11 Preclinical  No toxicity signal in multiple species: ― rabbits - 50X human blood level ― rats - 100X human blood level; 80X human blood level for 6 months ― dogs - 13X human blood level for 12 months ― no signs of intolerance, toxicity or behavioral changes at doses of 50, 100 and 200 mg/kg in a

  12. Slide 12: Pyridorin Development Program

    12 Target Indication:  Prevention or slowing the progression of diabetic nephropathy with type 2 diabetes Program:  Two identical, double-blind Phase 3 studies of 600 patients each Regulatory Agreements:  FDA Special Protocol Assessment  New endpoint of 50% increase in serum creatinine (decrease

  13. Slide 13: Overview of Phase 3 Study - PIONEER

    Objective:  Evaluate safety and efficacy of Pyridorin at a 300 mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population:  Type 2 diabetic patients  Baseline SCr greater than 1.3 and less than 3.0 mg/dL (eGFR > 20 ml

  14. Slide 14: PIONEER Primary and Secondary Endpoints

    Primary Endpoints:  Evaluate Pyridorin 300 mg twice daily (BID) efficacy compared to placebo in reducing the rate of progression of renal disease due to type 2 diabetes mellitus. With time to the composite endpoint consisting of the earliest event amongst: ― A serum creatinine (SCr) increase of ≥50

  15. Slide 15: PIONEER Phase 3 Interim Analysis

    PIONEER Phase 3 Interim Analysis 15 DSMB:  Monitoring unblinded safety information on an ongoing basis Interim Analysis 1* (mid-2016):  Independent biostatistician will undertake an interim analysis when at least 150 patients have completed a minimum of 12 months on treatment Interim Analysis 2* (

  16. Slide 16: Summary of Phase 2 Data

    Summary of Phase 2 Data

  17. Slide 17: Clinical Overview: Ph2 Data in Target Ph3 Population

    17 Clinical Overview: Ph2 Data in Target Ph3 Population (Type 2 Diabetes; SCr 1.3-3 mg/dL; Urinary Protein >1200 mg/g Cr; Stable SOC)

  18. Slide 18: PYR-206 – 24 Week Phase 2a Study (50 mg BID)

    18 PYR-206 – 24 Week Phase 2a Study (50 mg BID) PYR-206 Multi-center, randomized, double-blind, placebo- controlled trial to assess safety, tolerability and biological activity:  N = 128  Population: Type 1 or type 2 diabetes ― Baseline SCr ≤ 2.0 mg/dL ― Urinary Protein: Creatinine Ratio (PCR) >30

  19. Slide 19: Phase 2a PYR-206 Post-hoc Analysis

    NephroGenex 6 Month Phase 2a PYR-206 Post-hoc Analysis Mild to Moderate Diabetic Nephropathy – Dose 50 mg BID Patient Population Number of Subjects PYR, Placebo Baseline SCr PYR Placebo SCr Change from Baseline PYR Placebo Treatment Effect P value All Patients 65, 63 1.27  0.34 1.33  0.38 0.12  0

  20. Slide 20: PYR-205/207 – 24 Week Phase 2a Study (250 mg BID)

    20 PYR-205/207 – 24 Week Phase 2a Study (250 mg BID) PYR-205/207 Multi-center, randomized, double- blind, dose-escalating, placebo- controlled trial to assess safety, tolerability and biological activity:  N = 84  Population: Type 1 or type 2 diabetes ― SCr ≤ 2.0 mg/dL (PYR- 205); ― SCr >2 mg/dL a

  21. Slide 21: Phase 2a PYR-205/207 Pre-Specified Subgroup Analysis

    NephroGenex 6 Month Phase 2a PYR-205/207 Pre-Specified Subgroup Analysis Moderate to Advanced Diabetic Nephropathy – Dose 250 mg bid Note: Virtually all patients on standard of care at screening – ACEI/ARB therapy and blood pressure control Pyridorin at a 250 mg bid dose is well tolerated and slows

  22. Slide 22: PYR-210 – 52 Week Study - Baseline Characteristics

    22 PYR-210 – 52 Week Study - Baseline Characteristics

  23. Slide 23: PYR-210 – 52 wk Phase 2b study in Type 2 Diabetes

    23 PYR-210 – 52 wk Phase 2b study in Type 2 Diabetes with Overt Nephropathy (150 mg bd and 300 mg bd) PYR-210 Multi-center, randomized, double-blind, placebo- controlled trial to assess safety, tolerability and biological activity:  N = 317  Population: Type 2 diabetes with overt nephropathy ― Bas

  24. Slide 24: Phase 2b PYR-210 Pre-Specified Analysis: SOC vs. Non-SOC

    NephroGenex 12 Month Phase 2b PYR-210 Pre-Specified Analysis: SOC at Screening vs. Non-SOC at Screening Patients analysis Type 2 Diabetic Nephropathy Patients With and Without SOC1 at screening – 300 and 150 mg bid 1 SOC: ACEI/ARB therapy and blood pressure control. Patients not on SOC at screening

  25. Slide 25: Phase 2b PYR-210 Blood Pressure Changes of SOC vs. Non-SOC

    NephroGenex 12 month Phase 2b PYR 210 Blood Pressure Changes of SOC vs. Non-SOC at Screening analysis 25 Patients not on SOC at screening exhibited:  higher starting blood pressures,  more frequent BP medication changes, and  a reduction in BP during the treatment period all of which confounded S

  26. Slide 26: PYR-210 – 52wk Phase 2b Study: Established SOC vs not on SOC

    PYR-210 – 52wk Phase 2b Study on Type 2 Diabetes Established SOC Patients vs not on SOC 26 2 2.2 2.4 2.6 2.8 0 4 12 26 39 52 SOC Placebo SOC 150 mg SOC 300 mg Run-in Placebo Run-in 150 mg Run-in 300 mg Weeks M ean S C r (m g /d L )

  27. Slide 27: Phase 2b ACEI/ARB and Blood Pressure Medication Changes

    NephroGenex 12 month Phase 2b PYR 210 ACEI/ARB and Blood Pressure Medication Changes Prior to Randomization analysis 27 F re q u e n c y % Run-in Start of Trial - 6 mo F re q u e n c y % - 12 mo Established SOC - 9 mo - 3 mo Start of Trial - 6 mo -12 mo or earlier - 9 mo - 3 mo 60 20 60 20 40 40 Non

  28. Slide 28: Importance of Stable Standard of Care in DN trials

    28 Importance of Stable Standard of Care in DN trials

  29. Slide 29: Importance of Stable Standard of Care in DN trials

    29  The FDA is aware of this observed effect and requires sponsors to account for possible acute changes in SCr arising from ACEi/ARB/BP medication changes that could impact the SCr baseline and SCr-based calculated treatment effects.  A pre-specified analysis was included in the Phase 2b Statisti

  30. Slide 30: PYR-210 – Post-hoc analysis with Phase 3 endpoint

    30 PYR-210 – Post-hoc analysis with Phase 3 endpoint

  31. Slide 31: Pyridorin Safety Profile: PYR-210

    Pyridorin has a benign safety profile with the possible exception of a numerical increase in diarrhea and constipation with the higher dose of 300 mg BID Pyridorin Safety Profile: PYR-210 31 Most Reported Adverse Events Most Reported Serious Adverse Events  No meaningful differences between groups

  32. Slide 32: Acute Kidney Injury - IV Pyridorin

     Acute kidney injury (AKI) is a serious medical problem that results in substantial morbidity, prolonged hospitalization, increased medical costs, and significant mortality  The major causes of hospital-acquired AKI are decreased renal perfusion during surgery, contrast nephropathy and cancer ther

  33. Slide 33: AKI - Ischemia-reperfusion (I/R) Model

    33 PYR treatment was provided to mice in drinking water starting 72 h prior to injury and continued until sacrificed. AKI - Ischemia-reperfusion (I/R) Model NF = nephrectomy

  34. Slide 34: Exclusivity Patents and New Chemical Entity (NCE)

    No composition of matter claim since this molecule already exists in the human body in microscopic quantities U.S.  Method of use (including patient population and dosage) patent December 2028 (with anticipated patent term extension)  Method of manufacture patent February 2025  NCE - 5 year exclu

  35. Slide 35: NephroGenex Milestones

    NephroGenex Milestones 35 Achieved Expected  Feb-2014 Completion of Initial Public Offering  Mar-2014 Secured CRO  June-2014 Enrolled first patient in PIONEER pivotal Phase 3 trial  Nov-2014 Publication on new endpoint  Nov-2014 Poster presentations at American Society of Nephrology  Dec-2014

  36. Slide 36: Financial Snapshot

    Financial Snapshot Cash  As of September 30, 2015, approximately $20.9 million in cash, cash equivalents and investments  Raised an additional $5.0 million of net proceeds from a PIPE in November 2015  Sufficient cash balance to finance operations into mid-2016 NASDAQ: NRX (as of November 9, 2015

  37. Slide 37: Corporate Summary

    Corporate Summary 37 Diabetic nephropathy is a major unmet need with a significant healthcare financial burden Pharmaceutical company developing therapies that target the underlying cause of kidney disease  Oral Pyridorin – for the prevention or slowing the progression of diabetic nephropathy in pa

  38. Slide 38: Appendix

    Appendix

  39. Slide 39: Serum Creatinine and eGFR Definitions

    Definition  Serum Creatinine (SCr) – the level of creatinine, a by-product of muscle metabolism, circulating in the blood  Estimated Glomerular Filtration Rate (eGFR) – an estimate of the rate that the glomerulus filters blood based on circulating SCr levels corrected for age, sex, and race Compar

  40. Slide 40: Key Milestone: NKF/FDA Workshop

    40 Key Milestone: Dec 3-4 2012 NKF/FDA Workshop A doubling of serum creatinine is generally a late event in CKD and takes a long time to develop There is great interest in considering alternative endpoints for clinical trials:  to shorten the duration of clinical trials  to extend their applicatio

NephroGenex — Investor Presentation (November 2015) on 6ix